FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for UK-based media - If approved by the FDA, avelumab, an investigational immunotherapy, could be the first treatment indicated for patients with metastatic Merkel cell carcinoma (MCC) - Avelumab has previously received FDA Breakthrough Therapy and Fast ...